Bumrungrad Hospital Public Company Limited
and its subsidiaries
Review report and interim financial statements
For the three-month and nine-month periods ended
30 September 2015

Independent Auditor's Report on Review of Interim Financial Information

To the Shareholders of Bumrungrad Hospital Public Company Limited

I have reviewed the accompanying consolidated statement of financial position of Bumrungrad Hospital Public Company Limited and its subsidiaries as at 30 September 2015, the related consolidated statements of income and comprehensive income for the three-month and nine-month periods then ended, and the related consolidated statements of changes in shareholders' equity, and cash flows for the nine-month period then ended, as well as the condensed notes to the consolidated financial statements. I have also reviewed the separate financial information of Bumrungrad Hospital Public Company Limited for the same periods. Management is responsible for the preparation and presentation of this interim financial information in accordance with Thai Accounting Standard 34 *Interim Financial Reporting*. My responsibility is to express a conclusion on this interim financial information based on my review.

Scope of review

I conducted my review in accordance with Thai Standard on Review Engagements 2410, *Review of Interim Financial Information Performed by the Independent Auditor of the Entity*. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Thai Standards on Auditing and consequently does not enable me to obtain assurance that I would become aware of all significant matters that might be identified in an audit. Accordingly, I do not express an audit opinion.

Conclusion

Based on my review, nothing has come to my attention that causes me to believe that the accompanying interim financial information is not prepared, in all material respects, in accordance with Thai Accounting Standard 34 *Interim Financial Reporting*.

Sumalee Reewarabandith
Certified Public Accountant (Thailand) No. 3970

EY Office Limited
Bangkok: 29 October 2015

Bumrungrad Hospital Public Company Limited and its subsidiaries

Statement of financial position

(Unit: Thousand Baht)

		Consolidated financial statements		Separate financial statements	
	Note	30 September 2015	31 December 2014	30 September 2015	31 December 2014
		(Unaudited but reviewed)	(Audited)	(Unaudited but reviewed)	(Audited)
Assets					
Current assets					
Cash and cash equivalents		4,849,305	4,675,713	4,669,803	4,540,099
Short-term investments	*2*	2,312,002	1,922,000	2,302,000	1,802,000
Trade and other receivables	*2, 3*	2,260,782	1,525,212	2,259,794	1,524,709
Inventories		282,874	291,880	252,561	266,651
Prepaid expenses		59,823	66,489	54,010	63,553
Other current assets		20,899	18,097	16,777	14,114
Total current assets		9,785,685	8,499,391	9,554,945	8,211,126
Non-current assets					
Long-term loan to a related party	*2*	-	-	-	1,855
Investments in subsidiaries	*4*	-	-	1,517,456	1,542,861
Investments in associates	*5*	234,878	233,169	2,862	2,862
Other long-term investments		1,700	1,700	1,700	1,700
Property, plant and equipment	*6*	9,807,690	9,948,450	8,121,805	8,300,042
Intangible assets	*7*	150,891	146,343	156,334	155,678
Goodwill	*8*	123,539	111,968	-	-
Deferred tax assets		188,270	178,731	181,440	173,051
Other non-current assets		21,499	24,943	21,489	24,925
Total non-current assets		10,528,467	10,645,304	10,003,086	10,202,974
Total assets		20,314,152	19,144,695	19,558,031	18,414,100

The accompanying notes are an integral part of the financial statements.

Bumrungrad Hospital Public Company Limited and its subsidiaries

Statement of financial position (continued)

(Unit: Thousand Baht)

		Consolidated financial statements		Separate financial statements	
	Note	30 September 2015	31 December 2014	30 September 2015	31 December 2014
		(Unaudited but reviewed)	(Audited)	(Unaudited but reviewed)	(Audited)
Liabilities and shareholders' equity					
Current liabilities					
Trade and other payables	*2, 9*	770,937	860,237	769,160	854,355
Accrued physicians' fees		630,486	537,654	625,515	530,537
Accrued expenses		675,872	487,606	663,943	482,611
Income tax payable		198,383	369,829	191,715	355,329
Other current liabilities		75,300	66,687	64,953	55,579
Total current liabilities		2,350,978	2,322,013	2,315,286	2,278,411
Non-current liabilities					
Long-term loan from and interest payable to a related party	*2*	182,257	180,408	182,257	180,408
Long-term debentures	*2, 10*	4,976,572	4,971,982	4,976,572	4,971,982
Provision for long-term employee benefits	*11*	434,269	410,329	428,376	405,519
Total non-current liabilities		5,593,098	5,562,719	5,587,205	5,557,909
Total liabilities		7,944,076	7,884,732	7,902,491	7,836,320

The accompanying notes are an integral part of the financial statements.

Bumrungrad Hospital Public Company Limited and its subsidiaries

Statement of financial position (continued)

(Unit: Thousand Baht)

	Note	Consolidated financial statements		Separate financial statements	
		30 September 2015	31 December 2014	30 September 2015	31 December 2014
		(Unaudited but reviewed)	(Audited)	(Unaudited but reviewed)	(Audited)
Shareholders' equity					
Share capital	*12*				
Registered					
921,276,022 ordinary shares of Baht 1 each		921,276	921,251	921,276	921,251
(31 December 2014: 921,251,022 ordinary shares of Baht 1 each)					
1,426,663 preference shares of Baht 1 each		1,427	1,452	1,427	1,452
(31 December 2014: 1,451,663 preference shares of Baht 1 each)					
		922,703	922,703	922,703	922,703
Issued and paid-up					
728,625,559 ordinary shares of Baht 1 each		728,625	728,600	728,625	728,600
(31 December 2014: 728,600,559 ordinary shares of Baht 1 each)					
1,426,663 preference shares of Baht 1 each		1,427	1,452	1,427	1,452
(31 December 2014: 1,451,663 preference shares of Baht 1 each)					
		730,052	730,052	730,052	730,052
Premium on ordinary shares		285,568	285,568	285,568	285,568
Convertible bonds treated as equity securities	*2*	550,000	550,000	550,000	550,000
Retained earnings					
Appropriated - statutory reserve		92,275	92,275	92,275	92,275
Unappropriated		10,065,535	8,992,129	9,997,645	8,919,885
Other components of shareholders' equity		285,921	233,204	-	-
Equity attributable to owners of the Company		12,009,351	10,883,228	11,655,540	10,577,780
Non-controlling interests of the subsidiaries		360,725	376,735	-	-
Total shareholders' equity		12,370,076	11,259,963	11,655,540	10,577,780
Total liabilities and shareholders' equity		20,314,152	19,144,695	19,558,031	18,414,100
		-	-	-	-

The accompanying notes are an integral part of the financial statements.

.....

Directors

.....

(Unaudited but reviewed)

Bumrungrad Hospital Public Company Limited and its subsidiaries

Income statement

For the three-month period ended 30 September 2015

(Unit: Thousand Baht)

		Consolidated financial statements		Separate financial statements	
	Note	2015	2014	2015	2014
Revenues					
Revenues from hospital operations	*2*	4,315,021	4,054,337	4,197,623	3,942,408
Rental income	*2*	15,300	15,246	16,643	16,593
Interest income	*2*	33,008	31,120	32,517	30,000
Exchange gains		12,321	7,968	11,679	8,381
Other income	*2*	16,875	17,740	17,005	4,764
Total revenues		4,392,525	4,126,411	4,275,467	4,002,146
Expenses					
Cost of hospital operations	*2*	2,521,041	2,437,064	2,454,127	2,372,581
Administrative expenses	*2*	785,168	680,692	782,929	652,115
Total expenses		3,306,209	3,117,756	3,237,056	3,024,696
Profit before share of profit from investments					
in associates, finance cost and income tax expenses		1,086,316	1,008,655	1,038,411	977,450
Share of profit from investments in associates	*5*	755	720	-	-
Profit before finance cost and income tax expenses		1,087,071	1,009,375	1,038,411	977,450
Finance cost	*2*	(47,167)	(46,674)	(47,167)	(46,682)
Profit before income tax expenses		1,039,904	962,701	991,244	930,768
Income tax expenses	*13*	(198,792)	(190,231)	(194,575)	(184,128)
Profit for the period		841,112	772,470	796,669	746,640
Profit (loss) attributable to:					
Equity holders of the Company		843,499	767,539	796,669	746,640
Non-controlling interests of the subsidiaries		(2,387)	4,931		
		841,112	772,470		
Earnings per share	*14*				(Unit: Baht)
Basic earnings per share					
Profit attributable to equity holders of the Company		1.16	1.05	1.09	1.02
Diluted earnings per share					
Profit attributable to equity holders of the Company		0.97	0.88	0.92	0.86

The accompanying notes are an integral part of the financial statements.

(Unaudited but reviewed)

Bumrungrad Hospital Public Company Limited and its subsidiaries

Statement of comprehensive income

For the three-month period ended 30 September 2015

(Unit: Thousand Baht)

	Consolidated financial statements		Separate financial statements	
	2015	2014	2015	2014
Profit for the period	841,112	772,470	796,669	746,640
Other comprehensive income:				
Other comprehensive income to be reclassified				
to income statement in subsequent periods:				
Exchange differences on translation of				
financial statements in foreign currencies	44,773	(7,039)	-	-
Other comprehensive income for the period	44,773	(7,039)	-	-
Total comprehensive income for the period	885,885	765,431	796,669	746,640
Total comprehensive income attributable to:				
Equity holders of the Company	880,341	762,669	796,669	746,640
Non-controlling interests of the subsidiaries	5,544	2,762		
	885,885	765,431		

The accompanying notes are an integral part of the financial statements.

(Unaudited but reviewed)

Bumrungrad Hospital Public Company Limited and its subsidiaries

Income statement

For the nine-month period ended 30 September 2015

(Unit: Thousand Baht)

		Consolidated financial statements		Separate financial statements	
	Note	2015	2014	2015	2014
Revenues					
Revenues from hospital operations	*2*	13,055,275	11,405,411	12,689,598	11,123,488
Rental income	*2*	44,297	44,215	48,336	48,153
Interest income	*2*	107,194	102,261	104,547	102,730
Dividend income	*2, 4*	-	-	149,308	-
Exchange gains		37,494	31,762	34,451	34,546
Other income	*2*	66,634	76,288	63,666	68,176
Total revenues		13,310,894	11,659,937	13,089,906	11,377,093
Expenses					
Cost of hospital operations	*2*	7,627,044	6,921,458	7,419,213	6,765,169
Administrative expenses	*2*	2,247,539	2,048,989	2,205,684	1,970,325
Loss on diminution in value of investment in a subsidiary	*4*	-	-	29,500	-
Total expenses		9,874,583	8,970,447	9,654,397	8,735,494
Profit before share of profit (loss) from investments					
in associates, finance cost and income tax expenses		3,436,311	2,689,490	3,435,509	2,641,599
Share of profit (loss) from investments in associates	*5*	4,464	(3,943)	-	-
Profit before finance cost and income tax expenses		3,440,775	2,685,547	3,435,509	2,641,599
Finance cost	*2*	(139,358)	(139,179)	(139,358)	(138,372)
Profit before income tax expenses		3,301,417	2,546,368	3,296,151	2,503,227
Income tax expenses	*13*	(638,605)	(500,552)	(624,858)	(485,219)
Profit for the period		2,662,812	2,045,816	2,671,293	2,018,008
Profit (loss) attributable to:					
Equity holders of the Company		2,666,939	2,041,740	2,671,293	2,018,008
Non-controlling interests of the subsidiaries		(4,127)	4,076		
		2,662,812	2,045,816		
Earnings per share	*14*				(Unit: Baht)
Basic earnings per share					
Profit attributable to equity holders of the Company		3.66	2.80	3.67	2.77
Diluted earnings per share					
Profit attributable to equity holders of the Company		3.07	2.35	3.08	2.33

The accompanying notes are an integral part of the financial statements.

(Unaudited but reviewed)

Bumrungrad Hospital Public Company Limited and its subsidiaries

Statement of comprehensive income

For the nine-month period ended 30 September 2015

(Unit: Thousand Baht)

	Consolidated financial statements		Separate financial statements	
	2015	2014	2015	2014
Profit for the period	2,662,812	2,045,816	2,671,293	2,018,008
Other comprehensive income:				
Other comprehensive income to be reclassified to income statement in subsequent periods:				
Exchange differences on translation of financial statements in foreign currencies	40,834	(13,184)	-	-
Other comprehensive income for the period	40,834	(13,184)	-	-
Total comprehensive income for the period	2,703,646	2,032,632	2,671,293	2,018,008
Total comprehensive income attributable to:				
Equity holders of the Company	2,719,656	2,033,610	2,671,293	2,018,008
Non-controlling interests of the subsidiaries	(16,010)	(978)		
	2,703,646	2,032,632		

The accompanying notes are an integral part of the financial statements.

(Unaudited but reviewed)

Bumrungrad Hospital Public Company Limited and its subsidiaries

Statement of cash flows

For the nine-month period ended 30 September 2015

(Unit: Thousand Baht)

	Consolidated financial statements		Separate financial statements	
	2015	2014	2015	2014
Cash flows from operating activities				
Profit before tax	3,301,417	2,546,368	3,296,151	2,503,227
Adjustments to reconcile profit before tax to net cash				
provided by (paid from) operating activities:				
Depreciation and amortisation	772,028	747,018	740,522	728,423
Bad debts and allowance for doubtful accounts	58,410	31,462	58,667	30,098
Reduction of cost of inventories to net realisable value	1,364	-	-	-
(Gain) loss on sales of equipment	4,486	(987)	5,678	(1,287)
Loss on impairment of assets under construction	2,014	-	-	-
Long-term employee benefits expenses	55,423	60,900	54,298	60,288
Loss on diminution in value of investment in a subsidiary	-	-	29,500	-
Share of (profit) loss from investments in associates	(4,464)	3,943	-	-
Interest income	(107,194)	(102,261)	(104,547)	(102,730)
Dividend income	-	-	(149,308)	-
Amortisation of debenture issuing costs to interest expenses	4,590	4,381	4,590	4,381
Interest expenses	134,768	134,798	134,768	133,991
Profit from operating activities before changes				
in operating assets and liabilities	4,222,842	3,425,622	4,070,319	3,356,391
Operating assets (increase) decrease				
Trade and other receivables	(793,980)	(173,038)	(793,752)	(179,656)
Inventories	7,642	10,868	14,090	10,288
Prepaid expenses	6,666	(20,949)	9,543	(20,699)
Other current assets	(2,802)	22,093	(2,663)	22,035
Other non-current assets	3,444	2,143	3,436	2,143
Operating liabilities increase (decrease)				
Trade and other payables	(81,939)	(9,748)	(86,397)	2,506
Accrued physicians' fees	92,832	11,158	94,978	10,389
Accrued expenses	140,441	119,693	131,658	118,628
Other current liabilities	8,613	15,372	9,374	16,784
Provision for long-term employee benefits	(31,483)	(16,225)	(31,441)	(20,525)
Cash flows from operating activities	3,572,276	3,386,989	3,419,145	3,318,284
Cash paid for corporate income tax	(819,589)	(653,331)	(796,861)	(642,220)
Net cash flows from operating activities	2,752,687	2,733,658	2,622,284	2,676,064

The accompanying notes are an integral part of the financial statements.

(Unaudited but reviewed)

Bumrungrad Hospital Public Company Limited and its subsidiaries

Statement of cash flows (continued)

For the nine-month period ended 30 September 2015

(Unit: Thousand Baht)

	Consolidated financial statements		Separate financial statements	
	2015	2014	2015	2014
Cash flows from investing activities				
(Increase) decrease in short-term investments	(390,002)	1,087,730	(500,000)	1,052,730
Acquisition of investments in subsidiaries	-	(308,668)	(2,239)	(435,611)
Dividend received	-	-	149,308	-
Repayment debt of acquired subsidiary as at acquisition date	-	(85,705)	-	-
Cash receipt of capital increasing from non-controlling interest of the subsidiary	-	7,933	-	-
Cash increased from acquisitions of subsidiaries	-	3,286	-	-
Acquisition of equipment and repayment of construction and medical equipment payables	(563,250)	(927,296)	(509,865)	(918,207)
Acquisition of computer software	(21,198)	(7,048)	(19,799)	(6,172)
Proceeds from sales of equipment	844	10,996	844	10,957
Interest income	107,194	102,261	104,547	102,730
Net cash flows used in investing activities	(866,412)	(116,511)	(777,204)	(193,573)
Cash flows from financing activities				
Interest paid for long-term debentures	(115,735)	(115,735)	(115,735)	(115,735)
Dividend paid	(1,567,144)	(1,384,888)	(1,567,142)	(1,384,888)
Interest paid for convertible bonds treated as equity securities	(32,499)	(32,499)	(32,499)	(32,499)
Net cash flows used in financing activities	(1,715,378)	(1,533,122)	(1,715,376)	(1,533,122)
(Increase) decrease in translation adjustment	2,695	(16,388)	-	-
Net increase in cash and cash equivalents	173,592	1,067,637	129,704	949,369
Cash and cash equivalents at beginning of period	4,675,713	3,139,481	4,540,099	3,109,331
Cash and cash equivalents at end of period	4,849,305	4,207,118	4,669,803	4,058,700
	-		-	
Supplemental cash flow information				
Non-cash transactions				
Interest cost recorded as cost of assets	40,679	41,697	40,679	41,697
Decrease in construction and medical equipment payables	9,444	85,392	880	85,392
Convert long-term loan to a related party to investment in a subsidiary	-	-	1,855	-

The accompanying notes are an integral part of the financial statements.

(Unaudited but reviewed)

Bumrungrad Hospital Public Company Limited and its subsidiaries

Statement of changes in shareholders' equity

For the nine-month period ended 30 September 2015

(Unit: Thousand Baht)

	Consolidated financial statements											
	Equity attributable to owners of the Company											
							Other components of shareholders' equity					
							Other comprehensive income					
	Issued and paid-up share capital			Convertible	Retained earnings		Exchange differences on translation of financial statements in	Other paid-in capital of an associated	Total other components of shareholders'	Total equity attributable to owners of	Equity attributable to non-controlling interests of	Total shareholders'
	Ordinary shares	Preference shares	Premium on ordinary shares	bonds treated as equity securities	Appropriated - statutory reserve	Unappropriated	foreign currencies	company	equity	the Company	the subsidiaries	equity
Balance as at 1 January 2014	728,560	1,492	285,568	550,000	92,275	7,695,107	(8,210)	252,173	243,963	9,596,965	-	9,596,965
Preference shares converted to ordinary shares (Note 12)	40	(40)	-	-	-	-	-	-	-	-	-	-
Dividend paid (Note 16)	-	-	-	-	-	(1,386,891)	-	-	-	(1,386,891)	-	(1,386,891)
Cash receipt of capital increasing from non-controlling interest of the subsidiary	-	-	-	-	-	-	-	-	-	-	107,653	107,653
Increase in non-controlling interests of the subsidiaries due to purchase of investments in subsidiaries	-	-	-	-	-	-	-	-	-	-	264,954	264,954
Interest paid for convertible bonds treated as equity securities	-	-	-	-	-	(24,308)	-	-	-	(24,308)	-	(24,308)
Total comprehensive income for the period	-	-	-	-	-	2,041,740	(8,130)	-	(8,130)	2,033,610	(978)	2,032,632
Balance as at 30 September 2014	728,600	1,452	285,568	550,000	92,275	8,325,648	(16,340)	252,173	235,833	10,219,376	371,629	10,591,005
Balance as at 1 January 2015	728,600	1,452	285,568	550,000	92,275	8,992,129	(18,969)	252,173	233,204	10,883,228	376,735	11,259,963
Preference shares converted to ordinary shares (Note 12)	25	(25)	-	-	-	-	-	-	-	-	-	-
Dividend paid (Note 16)	-	-	-	-	-	(1,569,225)	-	-	-	(1,569,225)	-	(1,569,225)
Interest paid for convertible bonds treated as equity securities	-	-	-	-	-	(24,308)	-	-	-	(24,308)	-	(24,308)
Total comprehensive income for the period	-	-	-	-	-	2,666,939	52,717	-	52,717	2,719,656	(16,010)	2,703,646
Balance as at 30 September 2015	728,625	1,427	285,568	550,000	92,275	10,065,535	33,748	252,173	285,921	12,009,351	360,725	12,370,076
	-	-	-	-	-	-			-	-	-	-
	-	-	-	-	-	-			-	-	-	-

The accompanying notes are an integral part of the financial statements.

(Unaudited but reviewed)

Bumrungrad Hospital Public Company Limited and its subsidiaries

Statement of changes in shareholders' equity (continued)

For the nine-month period ended 30 September 2015

(Unit: Thousand Baht)

	Separate financial statements						
	Issued and paid-up share capital		Premium on ordinary shares	Convertible bonds treated as equity securities	Retained earnings		Total shareholders' equity
	Ordinary shares	Preference shares			Appropriated - statutory reserve	Unappropriated	
Balance as at 1 January 2014	728,560	1,492	285,568	550,000	92,275	7,680,779	9,338,674
Preference shares converted to ordinary shares (Note 12)	40	(40)	-	-	-	-	-
Dividend paid (Note 16)	-	-	-	-	-	(1,386,891)	(1,386,891)
Interest paid for convertible bonds treated as equity securities	-	-	-	-	-	(24,308)	(24,308)
Total comprehensive income for the period	-	-	-	-	-	2,018,008	2,018,008
Balance as at 30 September 2014	728,600	1,452	285,568	550,000	92,275	8,287,588	9,945,483
Balance as at 1 January 2015	728,600	1,452	285,568	550,000	92,275	8,919,885	10,577,780
Preference shares converted to ordinary shares (Note 12)	25	(25)	-	-	-	-	-
Dividend paid (Note 16)	-	-	-	-	-	(1,569,225)	(1,569,225)
Interest paid for convertible bonds treated as equity securities	-	-	-	-	-	(24,308)	(24,308)
Total comprehensive income for the period	-	-	-	-	-	2,671,293	2,671,293
Balance as at 30 September 2015	728,625	1,427	285,568	550,000	92,275	9,997,645	11,655,540
	-	-	-	-	-	-	-
	-	-	-	-	-	-	-

The accompanying notes are an integral part of the financial statements.

Bumrungrad Hospital Public Company Limited and its subsidiaries
Notes to interim consolidated financial statements
For the three-month and nine-month periods ended 30 September 2015

1. General information

1.1 The Company's general information

Bumrungrad Hospital Public Company Limited ("the Company") is a public company incorporated and domiciled in Thailand. The Company is principally engaged in hospital business, investment in other companies and rental of properties service. The registered office of the Company is at 33 Soi 3 (Nana Nua) Sukhumvit Road, Klongtoey Nua Sub District, Wattana District, Bangkok.

1.2 Basis of preparation of interim financial statements

These interim financial statements are prepared in accordance with Thai Accounting Standard No. 34 (revised 2014) Interim Financial Reporting, with the Company choosing to present condensed interim financial statements. However, the Company has presented the statements of financial position, income, comprehensive income, changes in shareholders' equity, and cash flows in the same format as that used for the annual financial statements.

The interim financial statements are intended to provide information additional to that included in the latest annual financial statements. Accordingly, they focus on new activities, events and circumstances so as not to duplicate information previously reported. These interim financial statements should therefore be read in conjunction with the latest annual financial statements.

The interim financial statements in Thai language are the official statutory financial statements of the Company. The interim financial statements in English language have been translated from the Thai language interim financial statements.

1.3 Basis of consolidation

These interim consolidated financial statements include the financial statements of Bumrungrad Hospital Public Company Limited and its subsidiaries (collectively "the Group") and have been prepared on the same basis as that applied for the consolidated financial statements for the year ended 31 December 2014, except for the change in the composition of the Group from the additional investments in subsidiaries as discussed in Note 4 to the financial statements.

1.4 New financial reporting standards

a. Financial reporting standards that became effective in the current period

The Company has adopted the revised (revised 2014) and new financial reporting standards issued by the Federation of Accounting Professions which became effective for fiscal years beginning on or after 1 January 2015. These financial reporting standards were aimed at alignment with the corresponding International Financial Reporting Standards, with most of the changes directed towards revision of wording and terminology, and provision of interpretations and accounting guidance to users of standards. The adoption of these financial reporting standards does not have any significant impact on the Group's financial statements. However, some of these standards involve changes to key principles, which are summarised below.

TAS 19 (revised 2014) Employee Benefits

This revised standard requires that the entity recognise actuarial gains and losses immediately in other comprehensive income while the existing standard allows the entity to recognise such gains and losses immediately in either profit or loss or other comprehensive income, or to recognise them gradually in profit or loss.

This revised standard does not have any impact on the financial statements as the Group already recognises actuarial gains and losses immediately in other comprehensive income.

TFRS 10 Consolidated Financial Statements

TFRS 10 prescribes requirements for the preparation of consolidated financial statements and replaces the content of TAS 27 Consolidated and Separate Financial Statements dealing with consolidated financial statements. This standard changes the principles used in considering whether control exists. Under this standard, an investor is deemed to have control over an investee if it has rights, or is exposed, to variable returns from its involvement with the investee, and it has the ability to direct the activities that affect the amount of its returns, even if it holds less than half of the shares or voting rights. This important change requires the management to exercise a lot of judgement when reviewing whether the Company and its subsidiaries have control over investees and determining which entities have to be included in preparation of the consolidated financial statements.

This standard does not have any impact on the Group's financial statements.

TFRS 11 Joint Arrangements

TFRS 11 supersedes TAS 31 Interests in Joint Ventures. This standard requires an entity investing in any other entity to determine whether the entity and other investors have joint control in the investment. When joint control exists, there is deemed to be a joint arrangement and the entity then needs to apply judgement to assess whether the joint arrangement is a joint operation or a joint venture and to account for the interest in the investment in a manner appropriate to the type of joint arrangement. If it is a joint operation, the entity is to recognise its shares of assets, liabilities, revenues and expenses of the joint operation, in proportion to its interest, in its separate financial statements. If it is a joint venture, the entity is to account for its investment in the joint venture using the equity method in the financial statements in which the equity method is applied or the consolidated financial statements (if any), and at cost in the separate financial statements.

This standard does not have any impact on the financial statements.

TFRS 12 Disclosure of Interests in Other Entities

This standard stipulates disclosures relating to an entity's interests in subsidiaries, joint arrangements and associates, including structured entities. This standard therefore has no financial impact on the financial statements of the Group.

TFRS 13 Fair Value Measurement

This standard provides guidance on how to measure fair value and stipulates disclosures related to fair value measurement. Entities are to apply the guidance under this standard if they are required by other financial reporting standards to measure their assets or liabilities at fair value. The effects of the adoption of this standard are to be recognised prospectively.

This standard does not have any significant impact on the Group's financial statements.

b. Financial reporting standards issued during the period and not yet effective

During the period, the Federation of Accounting Professions issued a number of the revised financial reporting standards (revised 2015) which is effective for fiscal years beginning on or after 1 January 2016. These financial reporting standards were aimed at alignment with the corresponding International Financial Reporting Standards. The Group's management believes that the revised financial reporting standards will not have any significant impact on the financial statements when they are initially applied.

1.5 Significant accounting policies

The interim financial statements are prepared using the same accounting policies and methods of computation as were used for the financial statements for the year ended 31 December 2014, except for the changes in accounting policies as a result of the adoption of new and revised standards, as discussed in Note 1.4 a. to the financial statements.

2. Related party transactions

During the periods, the Company and its subsidiaries had significant business transactions with related parties. Such transactions, which are summarised below, arose in the ordinary course of business and were concluded on commercial terms and bases agreed upon between the Company and those related parties.

(Unit: Thousand Baht)

	Consolidated financial statements		Separate financial statements		Transfer pricing policy
	For the three-month periods ended 30 September		For the three-month periods ended 30 September		
	2015	2014	2015	2014	
Transactions with subsidiaries					
(eliminated from the consolidated financial statements)					
Medical service income	-	-	7,827	6,181	Market price
Professional service income	-	-	3,698	367	Actual paid
Rental income	-	-	1,350	1,350	As per contracts 2.1)
Lab service expense	-	-	50	42	Market price
Pharmacy expense	-	-	1,897	2,071	Market price
Training expense	-	-	49,981	20,875	Cost plus margin
Transactions with associates					
Consulting income	10	29	10	29	As per contract 2.2)
Interest expense on long-term loans	538	667	538	667	1.38% p.a. (2014: 1.50% p.a.)
Transactions with related parties					
Medical service income	28,163	24,413	28,163	24,413	Market price
Rental income	589	545	589	545	Market price
Interest income on short-term investments	12,725	3,472	12,485	2,916	1.88% to 3.10% p.a. (2014: 2.40% to 3.00% p.a.)
Other income	177	181	177	181	At cost
Lab service expense	3,043	856	3,043	856	Market price
Purchase of medicine and medical supplies	3,108	3,059	3,108	3,059	Market price
Donation expense	6,000	6,000	6,000	6,000	-
Insurance expense	8,944	8,325	8,903	8,256	As per insurance policies
Credit card commission fees	29,907	29,482	28,898	28,871	Market price

(Unit: Thousand Baht)

	Consolidated financial statements		Separate financial statements		Transfer pricing policy
	For the three-month periods ended 30 September		For the three-month periods ended 30 September		
	2015	2014	2015	2014	
Legal advisory fee	560	881	560	822	Market price
Service fee	657	254	657	254	Market price
Interest expense on long-term debentures	11,656	11,656	11,656	11,656	4.13% to 4.97% p.a.
Interest expense on convertible bonds	8,192	8,192	8,192	8,192	10.00% and 1.00% p.a.

(Unit: Thousand Baht)

	Consolidated financial statements		Separate financial statements		Transfer pricing policy
	For the nine-month periods ended 30 September		For the nine-month periods ended 30 September		
	2015	2014	2015	2014	
Transactions with subsidiaries					
(eliminated from the consolidated financial statements)					
Medical service income	-	-	23,284	17,055	Market price
Professional service income	-	-	7,180	1,081	Actual paid
Rental income	-	-	4,050	4,365	As per contracts 2.1)
Interest income on long-term loans	-	-	-	3,346	3.25% p.a.
Dividend income	-	-	149,308	-	As declared
Sales of equipment	-	-	154	-	Cost plus margin
Lab service expense	-	-	169	103	Market price
Pharmacy expense	-	-	5,753	5,546	Market price
Training expense	-	-	103,511	51,117	Cost plus margin
Transactions with associates					
Consulting income	33	163	33	163	As per contract 2.2)
Interest expense on long-term loans	1,850	2,088	1,850	2,088	1.38% to 1.50% p.a. (2014: 1.50% to 2.0% p.a.)
Transactions with related parties					
Medical service income	61,825	69,281	61,825	69,281	Market price
Rental income	1,769	1,636	1,769	1,636	Market price
Interest income on short-term investments	37,406	14,953	35,745	12,891	1.88% to 3.10% p.a. (2014: 2.25% to 3.00% p.a.)
Other income	565	561	565	561	At cost
Lab service expense	6,792	2,034	6,792	2,030	Market price
Purchase of medicine and medical supplies	9,766	9,349	9,766	9,349	Market price
Donation expense	18,000	18,000	18,000	18,000	-

(Unit: Thousand Baht)

	Consolidated financial statements		Separate financial statements		Transfer pricing policy
	For the nine-month periods ended 30 September		For the nine-month periods ended 30 September		
	2015	2014	2015	2014	
Insurance expense	26,382	24,850	26,238	24,651	As per insurance policies
Credit card commission fees	92,842	85,650	89,742	83,134	Market price
Legal advisory fee	1,907	4,493	1,865	3,660	Market price
Construction consulting fee	-	578	-	578	Baht 0.1 million per month as stated in the agreement
Service fee	2,054	1,045	2,054	1,045	Market price
Interest expense on long-term debentures	34,588	34,588	34,588	34,588	4.13% to 4.97% p.a.
Interest expense on convertible bonds	24,308	24,308	24,308	24,308	10.00% and 1.00% p.a.
Interest expense on long-term loan	-	807	-	-	3.25% p.a.

2.1) Subsidiaries have leased building spaces and office equipment from the Company for use in their operations, as detailed below.

(Unit: Thousand Baht)

Company's name	Rent assets	Rental fee per month	
		2015	2014
Vitallife Corporation Ltd.	Building spaces	350	350
Bumrungrad Health Network Co., Ltd. (formerly known as "Bumrungrad Personnel Development Center Co., Ltd.")	Building spaces and office equipment	-	100 - 204*
Bumrungrad Personnel Development and Training Center Co., Ltd.	Building spaces	100	-

*The rental agreement starts in February 2014.

2.2) The Company entered into a Consulting Support Agreement with an associate (Bumrungrad International Ltd.). The associate is obliged to pay a fee at a fixed rate amounting to Baht 0.2 million per annum, as stipulated in the agreement, and additional fee for consulting service provided by employees of the Company to the associate at the rates per agreement multiplied with actual hours worked. The agreement will expire in accordance with the conditions in the agreement.

The balances of the accounts between the Company and those related parties are as follows.

(Unit: Thousand Baht)

	Consolidated financial statements		Separate financial statements	
	30 September 2015	31 December 2014	30 September 2015	31 December 2014
Short-term investments - Fixed deposits with a local commercial bank				
Related company (common director)	2,312,002	1,902,000	2,302,000	1,802,000
Trade and other receivables - related parties (Note 3)				
Subsidiaries	-	-	14,819	14,144
Associates	3	66	3	66
Related companies (common director)	4,998	1,161	4,998	1,161
Total	5,001	1,227	19,820	15,371
Trade and other payables - related parties (Note 9)				
Subsidiaries	-	-	15,706	13,395
Long-term loan to a related party				
Subsidiary	-	-	-	1,855
Long-term loan from and interest payable to a related party				
Associate	182,257	180,408	182,257	180,408
Long-term debentures (Note 10)				
Related companies (major shareholder and common director)	955,000	955,000	955,000	955,000
Convertible bonds treated as equity securities				
Related company (common director)	550,000	550,000	550,000	550,000

Long-term loan to a related party

As at 31 December 2014, long-term loan to a subsidiary (Life and Longevity Ltd.) is in the form of promissory notes denominated in Swiss francs, amounting to CHF 51,000, bearing no interest and due at call. The Company provided this loan to the subsidiary as its investment in overseas and the loan is therefore classified as a long-term loan. During the period, the Company converted the long-term loan to additional equity in the subsidiary, as discussed in Note 4.2 to the financial statements.

Long-term loan from and interest payable to a related party

On 1 April 2013, the Company and two other shareholders of Bumrungrad International Ltd. entered into a loan agreement with Bumrungrad International Ltd., which is the Company's associate, granting them loans totaling Baht 394.8 million, of which the Company's portion is Baht 176.4 million and due at call. The loan carries interest at the 1-year fixed deposit rate of a local commercial bank. Interest is due annually. The Company's management believes that the associate neither plans nor is likely to call for settlement in the foreseeable future; hence the loan is classified as long-term loan.

During the nine-month period ended 30 September 2015, movements of long-term loan from and interest payable to an associate were as follows.

(Unit: Thousand Baht)

	Consolidated financial statements/ Separate financial statements		
	Balance as at 1 January 2015	Increase during the period	Balance as at 30 September 2015
Principal	176,400	-	176,400
Interest payable	4,008	1,849	5,857
Total	180,408	1,849	182,257

Directors and management's benefits

During the three-month and nine-month periods ended 30 September 2015 and 2014, the Group had employee benefit expenses payable to their directors and management as follows.

(Unit: Thousand Baht)

	Consolidated financial statements		Separate financial statements	
	For the three-month periods ended 30 September		For the three-month periods ended 30 September	
	2015	2014	2015	2014
Short-term employee benefits	26,657	31,407	23,742	30,544
Other long-term benefits	-	2	-	2
Termination benefits	1,000	1,563	928	1,548
Total	27,657	32,972	24,670	32,094

(Unit: Thousand Baht)

	Consolidated financial statements		Separate financial statements	
	For the nine-month periods ended 30 September		For the nine-month periods ended 30 September	
	2015	2014	2015	2014
Short-term employee benefits	78,343	99,908	70,982	96,907
Other long-term benefits	1	7	1	7
Termination benefits	3,726	6,296	3,512	6,251
Total	82,070	106,211	74,495	103,165

3. Trade and other receivables

(Unit: Thousand Baht)

	Consolidated financial statements		Separate financial statements	
	30 September 2015	31 December 2014	30 September 2015	31 December 2014
Trade receivables - related parties				
Aged on the basis of due dates				
Not yet due	4,702	833	5,261	970
Past due				
1 - 30 days	-	-	-	54
Total trade receivables - related parties	4,702	833	5,261	1,024
Trade receivables - unrelated parties				
Aged on the basis of due dates				
Not yet due	943,402	489,737	938,433	483,888
Past due				
1 - 30 days	229,011	281,815	223,564	279,227
31 - 60 days	8,071	146,993	7,379	142,314
61 - 90 days	247,961	120,523	243,897	120,119
91 - 180 days	350,553	232,722	350,069	232,339
181 - 365 days	334,986	194,403	334,867	193,621
More than 365 days	254,805	148,610	254,211	147,531
Total	2,368,789	1,614,803	2,352,420	1,599,039
Less: Allowance for doubtful accounts	(118,253)	(98,464)	(117,641)	(97,345)
Total trade receivables - unrelated parties, net	2,250,536	1,516,339	2,234,779	1,501,694
Total trade receivables - net	2,255,238	1,517,172	2,240,040	1,502,718
Other receivables				
Advances and loans to employees	5,245	7,646	5,195	7,644
Accrued income - related parties	299	394	9,983	14,347
Other receivables - related parties	-	-	4,576	-
Total other receivables	5,544	8,040	19,754	21,991
Trade and other receivables - net	2,260,782	1,525,212	2,259,794	1,524,709

4. Investments in subsidiaries

Details of investments in subsidiaries as presented in the separate financial statements are as follows.

(Unit: Thousand Baht)

Company's name	Paid-up capital		Shareholding percentage		Cost		Allowance for loss on diminution in value		Carrying amounts based on cost method - net	
	30 September 2015	31 December 2014	30 September 2015	31 December 2014	30 September 2015	31 December 2014	30 September 2015	31 December 2014	30 September 2015	31 December 2014
			%	%						
Vitallife Corporation Ltd.	Baht 31.5 million	Baht 31.5 million	100.00	100.00	25,610	25,610	-	-	25,610	25,610
Asia Global Research Co., Ltd.	Baht 50.0 million	Baht 50.0 million	100.00	100.00	50,000	50,000	50,000	50,000	-	-
Ruenmongkol Co., Ltd.	Baht 340.0 million	Baht 340.0 million	100.00	100.00	1,045,034	1,045,034	-	-	1,045,034	1,045,034
Bumrungrad Health Network Co., Ltd. (formerly known as "Bumrungrad Personnel Development Center Co., Ltd.")	Baht 5.0 million	Baht 5.0 million	100.00	100.00	5,000	5,000	-	-	5,000	5,000
Bumrungrad Personnel Development and Training Center Co., Ltd.	Baht 5.0 million	Baht 5.0 million	100.00	100.00	5,000	5,000	-	-	5,000	5,000
Asia Global Health Ltd.	HKD 7.1 million	HKD 7.1 million	100.00	100.00	31,558	31,558	29,500	-	2,058	31,558
Life and Longevity Ltd.	USD 62,000	USD 1	100.00	100.00	2,143	48	-	-	2,143	48
Health Horizons Enterprises Pte. Ltd.	USD 16.6 million	USD 16.6 million	80.00	80.00	430,611	430,611	-	-	430,611	430,611
Bumrungrad Services Co., Ltd.	Baht 2.0 million	-	100.00	-	2,000	-	-	-	2,000	-
Total					1,596,956	1,592,861	79,500	50,000	1,517,456	1,542,861

During the nine-month period ended 30 September 2015, the Company received dividend from Vitallife Corporation Ltd. amounting to Baht 149.3 million (2014: nil).

During the nine-month period ended 30 September 2015, the Company considered to set allowance for loss on diminution in value of investment in Asia Global Health Ltd. amounting to Baht 29.5 million because it had capital deficit for several years.

4.1 Establishments of new subsidiaries

Bumrungrad Services Co., Ltd.

On 30 April 2015, the Company set up and registered a new subsidiary, Bumrungrad Services Co., Ltd., incorporated in Thailand with a registered share capital of Baht 2.0 million, comprising of 200,000 common shares with par value of Baht 10 each. The Company's shareholding percentage represents 100% of total issued and paid-up share capital. The Company paid for common shares of the subsidiary on 18 August 2015.

The investment was made in accordance with a resolution of the Investment Committee Meeting held on 25 February 2015, which approved the Company's establishment of the new subsidiary to be engaged in referral services to both domestic and foreign patients.

Bumrungrad Myanmar Co., Ltd.

On 14 May 2015, Bumrungrad Health Network Co., Ltd. (formerly known as "Bumrungrad Personnel Development Center Co., Ltd.") ("BHN"), the Company's wholly-owned subsidiary which is registered in Thailand, was granted permission to temporarily set up and register a new subsidiary, Bumrungrad Myanmar Co., Ltd. ("BM"), incorporated in Myanmar with a registered share capital of USD 1.3 million, comprised of 1,325,750 common shares with par value of USD 1 each. Thereafter, BM obtained a business permit from the Myanmar Investment Commission on 25 September 2015 and obtained a certificate of permanent incorporation of BM from the Directorate of Investment and Company Administration on 21 October 2015. As at 30 September 2015, BM had 187,500 paid-up shares with a par value of USD 1 each and BHN's shareholding represented 80% of the total issued and paid-up share capital, with an investment of Baht 5.1 million.

The investment was made in accordance with a resolution of the Investment Committee Meeting held on 7 November 2014, which approved the establishment of the new subsidiary to engage in the operation of a private clinic and diagnostic services.

4.2 Call up of a subsidiary's shares

Life and Longevity Ltd.

On 10 March 2015, Life and Longevity Ltd., the Company's wholly-owned subsidiary which is registered in Hong Kong Special Administrative Region of the People's Republic of China, registered an increase of its capital and called up USD 61,999, or equivalent to Baht 2.1 million, for the additional common shares. The Company made payment for the additional common shares by converting to equity a long-term loan to the subsidiary in the form of promissory notes denominated in Swiss francs, amounting to CHF 51,000, and paid the remaining cost on 4 June 2015.

Bumrungrad Mongolia LLC

On 16 September 2015, Health Horizons Enterprises Pte. Ltd., a subsidiary in Singapore, 80% owned by the Company, acquired 100% of the additional common shares of Bumrungrad Mongolia LLC, a subsidiary in Mongolia, amounting to MNT 60 million or equivalent to Baht 1 million.

5. Investments in associates

5.1 Details of investments in associates

(Unit: Thousand Baht)

			Consolidated financial statements					
			Shareholding percentage		Cost		Carrying amounts based on equity method	
Company's name	Nature of business	Country of incorporation	30 September 2015	31 December 2014	30 September 2015	31 December 2014	30 September 2015	31 December 2014
			%	%				
Bumrungrad International Ltd.	Temporary cease its operation	Thailand	31.50	31.50	1,447	1,447	234,138	232,226
CDE Trading Ltd.	Temporary cease its operation	Thailand	30.00	30.00	5,415	5,415	740	943
Total					6,862	6,862	234,878	233,169

(Unit: Thousand Baht)

	Separate financial statements							
	Shareholding percentage		Cost		Allowance for loss on diminution in value		Carrying amounts based on cost method - net	
Company's name	30 September 2015	31 December 2014	30 September 2015	31 December 2014	30 September 2015	31 December 2014	30 September 2015	31 December 2014
	%	%						
Bumrungrad International Ltd.	31.50	31.50	1,447	1,447	-	-	1,447	1,447
CDE Trading Ltd.	30.00	30.00	5,415	5,415	4,000	4,000	1,415	1,415
Total			6,862	6,862	4,000	4,000	2,862	2,862

5.2 Share of profit (loss) and dividend received

During the periods, the Company recognised its share of profit (loss) from investments in associates in the consolidated financial statements as follows.

(Unit: Thousand Baht)

Company's name	For the three-month periods ended 30 September		For the nine-month periods ended 30 September	
	2015	2014	2015	2014
Bumrungrad International Ltd.	(110)	181	1,912	(6,464)
CDE Trading Ltd.	865	539	2,552	2,521
Total	755	720	4,464	(3,943)

During the three-month and nine-month periods ended 30 September 2015 and 2014, the Company had no dividend received from the associates.

5.3 Summarised financial information of associates

Financial information of the associates is summarised below.

(Unit: Million Baht)

Company's name	Paid-up capital as at 30 September 2015	Paid-up capital as at 31 December 2014	Total assets as at 30 September 2015	Total assets as at 31 December 2014	Total liabilities as at 30 September 2015	Total liabilities as at 31 December 2014	Total revenues for the nine-month periods ended 30 September 2015	Total revenues for the nine-month periods ended 30 September 2014	Profit (loss) for the nine-month periods ended 30 September 2015	Profit (loss) for the nine-month periods ended 30 September 2014
Bumrungrad International Ltd.	4.6	4.6	753.9	754.9	10.6	17.7	10.2	12.8	6.0	(20.5)
CDE Trading Ltd.	2.5	2.5	2.5	5.8	-	2.5	-	-	(0.7)	(0.8)

6. Property, plant and equipment

(Unit: Thousand Baht)

	Consolidated financial statements	Separate financial statements
Net book value as at 1 January 2015	9,948,450	8,300,042
Acquisitions during period - at cost	553,806	508,985
Capitalisation of interest cost	40,679	40,679
Transferred to computer software	(31,740)	(31,740)
Disposals during period - net book value at disposal date	(5,330)	(6,522)
Depreciation for the period	(720,878)	(689,639)
Allowance for loss on impairment	(2,014)	-
Translation adjustments	24,717	-
Net book value as at 30 September 2015	9,807,690	8,121,805

As at 30 September 2015, the Company had an outstanding balance of land, work under construction of building and building improvement of Baht 1,121.0 million (31 December 2014: Baht 1,150.1 million), which have been financed by long-term debentures and borrowing costs totaling Baht 40.7 million were capitalised during the nine-month period ended 30 September 2015 (2014: Baht 41.7 million). The weighted average rate used to determine the amount of borrowing costs eligible for capitalisation was 4.87% p.a.

7. Intangible assets

(Unit: Thousand Baht)

	Consolidated financial statements	Separate financial statements
Net book value as at 1 January 2015	146,343	155,678
Acquisitions during period - at cost	21,198	19,799
Transferred from equipment	31,740	31,740
Amortisation for the period	(51,150)	(50,883)
Realised gain on sales of software in the past	2,755	-
Translation adjustments	5	-
Net book value as at 30 September 2015	150,891	156,334

8. Goodwill

Goodwill resulted from the acquisition by Health Horizons Enterprises Pte. Ltd. ("HHE"), an overseas subsidiary that is 80% owned by the Company, of a 100% interest in the common shares of Bumrungrad Mongolia LLC ("BML") on 28 March 2014. BML holds 51% of the common shares of Seoul Seniors Tower LLC ("SST"), which operates Ulan Bator Songdo Hospital in Mongolia. The excess of the purchase price over the net value of the tangible assets acquired was allocated as goodwill. The amount of goodwill is USD 3.4 million, which mainly comprises the value of expected synergies from customer base expansion.

The change in the goodwill account is due to the impact of exchange differences on translation of the foreign operation's financial statements.

9. Trade and other payables

(Unit: Thousand Baht)

	Consolidated financial statements		Separate financial statements	
	30 September 2015	31 December 2014	30 September 2015	31 December 2014
Trade payables - unrelated parties	671,400	753,834	652,713	745,308
Construction and medical equipment payables	71,903	81,347	71,903	72,783
Other payables - related parties	-	-	15,706	13,395
Other payables - unrelated parties	27,634	25,056	28,838	22,869
Total	770,937	860,237	769,160	854,355

10. Long-term debentures

(Unit: Thousand Baht)

Series	Maturity date	No. of units	Par value	Interest rate	Term of interest payment	Carrying amount 30 September 2015	Carrying amount 31 December 2014
		(Thousand units)	(Baht)	(% p.a.)			
1	Entirely redeemed on 20 December 2016 (5 years)	1,500	1,000	4.13	Semi-annual	1,500,000	1,500,000
2	Entirely redeemed on 20 December 2018 (7 years)	1,000	1,000	4.59	Semi-annual	1,000,000	1,000,000
3	Entirely redeemed on 20 December 2021 (10 years)	2,500	1,000	4.97	Semi-annual	2,500,000	2,500,000
Total						5,000,000	5,000,000
Less: Deferred debenture issuing costs						(23,428)	(28,018)
Long-term debentures - net						4,976,572	4,971,982

The long-term debentures are unsecured and unsubordinated debentures in Baht currency with fixed interest rates. Their fair value as at 30 September 2015 amounted to Baht 5,296.9 million (31 December 2014: Baht 5,264.6 million).

Under the terms and conditions of the debentures, the Company has to comply with certain restrictions and maintain certain financial ratios which include:

a) maintenance of a net debt to equity ratio not exceeding 1.75:1

b) maintenance of a net debt to EBITDA ratio not exceeding 3.25:1

11. Provision for long-term employee benefits

(Unit: Thousand Baht)

	Consolidated financial statements	Separate financial statements
As at 1 January 2015	410,329	405,519
Increase during the period	55,423	54,522
Utilised	(31,483)	(31,441)
Transfer of defined benefit obligation to a subsidiary	-	(224)
As at 30 September 2015	434,269	428,376

12. Share capital

In the first quarter of 2015, 25,000 preference shares (2014: 40,000 shares) were converted into ordinary shares at ratio of one preference share to one ordinary share. The Company registered this conversion with the Ministry of Commerce on 3 March 2015.

13. Income tax

Interim corporate income tax was calculated on profit before income tax for the period, using the estimated effective tax rate for the year.

Income tax expenses for the three-month and nine-month periods ended 30 September 2015 and 2014 are made up as follows.

(Unit: Thousand Baht)

	Consolidated financial statements		Separate financial statements	
	For the three-month periods ended 30 September		For the three-month periods ended 30 September	
	2015	2014	2015	2014
Current income tax:				
Interim corporate income tax charge	204,460	201,284	200,087	192,002
Deferred tax:				
Relating to origination and reversal of temporary differences	(5,668)	(11,053)	(5,512)	(7,874)
Income tax expenses reported in the income statements	198,792	190,231	194,575	184,128

(Unit: Thousand Baht)

	Consolidated financial statements		Separate financial statements	
	For the nine-month periods ended 30 September		For the nine-month periods ended 30 September	
	2015	2014	2015	2014
Current income tax:				
Interim corporate income tax charge	647,886	517,177	633,246	501,583
Deferred tax:				
Relating to origination and reversal of temporary differences	(9,281)	(16,625)	(8,388)	(16,364)
Income tax expenses reported in the income statements	638,605	500,552	624,858	485,219

14. Earnings per share

Basic earnings per share is calculated by dividing profit for the period attributable to equity holders of the Company (excluding other comprehensive income) by the weighted average number of ordinary shares in issue during the period.

Diluted earnings per share is calculated by dividing profit for the period attributable to equity holders of the Company (excluding other comprehensive income) by the weighted average number of ordinary shares in issue during the period plus the weighted average number of ordinary shares which would need to be issued to convert all dilutive potential ordinary shares into ordinary shares. The calculation assumes that the conversion took place either at the beginning of the period or on the date the potential ordinary shares were issued.

The following tables set forth the computation of basic and diluted earnings per share.

	Consolidated financial statements					
	For the three-month periods ended 30 September					
	Profit for the period		Weighted average number of ordinary shares		Earnings per share	
	2015	2014	2015	2014	2015	2014
	(Thousand Baht)	(Thousand Baht)	(Thousand shares)	(Thousand shares)	(Baht)	(Baht)
Basic earnings per share						
Profit attributable to equity holders of the Company	843,499	767,539	728,625	728,600	1.16	1.05
Effect of dilutive potential ordinary shares						
Preference shares	-	-	1,427	1,452		
Convertible bonds	-	-	137,363	137,363		
Diluted earnings per share						
Profit of ordinary shareholders assuming the conversion of dilutive potential ordinary shares	843,499	767,539	867,415	867,415	0.97	0.88

	Separate financial statements					
	For the three-month periods ended 30 September					
	Profit for the period		Weighted average number of ordinary shares		Earnings per share	
	2015	2014	2015	2014	2015	2014
	(Thousand Baht)	(Thousand Baht)	(Thousand shares)	(Thousand shares)	(Baht)	(Baht)
Basic earnings per share						
Profit attributable to equity holders of the Company	796,669	746,640	728,625	728,600	1.09	1.02
Effect of dilutive potential ordinary shares						
Preference shares	-	-	1,427	1,452		
Convertible bonds	-	-	137,363	137,363		
Diluted earnings per share						
Profit of ordinary shareholders assuming the conversion of dilutive potential ordinary shares	796,669	746,640	867,415	867,415	0.92	0.86

	Consolidated financial statements					
	For the nine-month periods ended 30 September					
	Profit for the period		Weighted average number of ordinary shares		Earnings per share	
	2015	2014	2015	2014	2015	2014
	(Thousand Baht)	(Thousand Baht)	(Thousand shares)	(Thousand shares)	(Baht)	(Baht)
Basic earnings per share						
Profit attributable to equity holders of the Company	2,666,939	2,041,740	728,620	728,591	3.66	2.80
Effect of dilutive potential ordinary shares						
Preference shares	-	-	1,432	1,461		
Convertible bonds	-	-	137,363	137,363		
Diluted earnings per share						
Profit of ordinary shareholders assuming the conversion of dilutive potential ordinary shares	2,666,939	2,041,740	867,415	867,415	3.07	2.35

	Separate financial statements					
	For the nine-month periods ended 30 September					
	Profit for the period		Weighted average number of ordinary shares		Earnings per share	
	2015	2014	2015	2014	2015	2014
	(Thousand Baht)	(Thousand Baht)	(Thousand shares)	(Thousand shares)	(Baht)	(Baht)
Basic earnings per share						
Profit attributable to equity holders of the Company	2,671,293	2,018,008	728,620	728,591	3.67	2.77
Effect of dilutive potential ordinary shares						
Preference shares	-	-	1,432	1,461		
Convertible bonds	-	-	137,363	137,363		
Diluted earnings per share						
Profit of ordinary shareholders assuming the conversion of dilutive potential ordinary shares	2,671,293	2,018,008	867,415	867,415	3.08	2.33

15. Segment information

Operating segment information is reported in a manner consistent with the internal reports that are regularly reviewed by the chief operating decision maker in order to make decisions about the allocation of resources to the segment and assess its performance.

The one main reportable operating segment of the Group is hospital and health care center and the geographical areas of its operations are Thailand and Mongolia. Segment performance is measured based on operating profit or loss, on a basis consistent with that used to measure operating profit or loss in the financial statements. As a result, all of the revenues, operating profits and assets as reflected in these financial statements pertain exclusively to the aforementioned reportable operating segment.

16. Dividend paid

The Company declared dividend during the nine-month periods ended 30 September 2015 and 2014 as follows.

Dividend	Approved by	Dividend paid	Dividend per share
		(Thousand Baht)	(Baht)
Final dividends for 2013	Annual General Meeting of the shareholders on 29 April 2014	875,859	1.20
Interim dividends for 2014	Board of Director's meeting on 8 August 2014	511,032	0.70
Total for 2014		1,386,891	
Final dividends for 2014	Annual General Meeting of the shareholders on 29 April 2015	912,557	1.25
Interim dividends for 2015	Board of Director's meeting on 10 August 2015	656,668	0.90
Total for 2015		1,569,225	

17. Commitments and contingent liabilities

17.1 Capital commitments

As at 30 September 2015, the Company has capital commitments to pay a total of Baht 170.6 million (31 December 2014: Baht 163.4 million) in relation to the design and renovation agreements of buildings and Baht 134.9 million (31 December 2014: Baht 150.0 million) in respect of purchase of medical instruments and hospital equipment.

17.2 Operating lease and long-term service commitments

The Company has entered into operating lease agreements in respect of the lease of lands, buildings, office space, vehicles and equipment and long-term service agreements. The terms of the agreements are generally between 1 and 30 years.

Future minimum payments required under the above agreements were as follows.

(Unit: Million Baht)

Details of commitments	Payable within 1 year		1 to 5 years		More than 5 years		Total	
	30 September 2015	31 December 2014	30 September 2015	31 December 2014	30 September 2015	31 December 2014	30 September 2015	31 December 2014
1) Nursing dormitory land rental expense (shall be extended for a further period of 30 years)	2	2	6	7	3	4	11	13
2) Lease of office space	21	31	38	51	-	-	59	82
3) Maintenance service fee for medical instruments	134	136	93	137	-	-	227	273
4) Rental and maintenance service fee for cars	9	11	14	14	-	-	23	25
5) Fee to a bank which is bondholders' representative	-	-	1	1	-	-	1	1
6) Service fee for medical treatment information database	39	30	215	199	-	35	254	264

17.3 Commitments from other contract

The Company entered into the medical equipment utilisation contract with a local company. The contract covers period of 7 years (expire in 2021) and under the conditions of the contract, the Company is required to purchase medical supplies and services to use with the medical equipment at the prices specified in the contract in total throughout the period of the contract. As at 30 September 2015, the outstanding amount of medical supplies and services that the Company is required to purchase in accordance with the contract is Baht 262.2 million (31 December 2014: Baht 319.0 million).

17.4 Uncalled portion of investments in subsidiaries

The Company and its subsidiary have commitments in respect of the uncalled portion of investments in overseas subsidiaries as below.

Company's name	Country of incorporation	Uncalled portion of investments	
		30 September 2015	31 December 2014
Asia Global Health Ltd.	Hong Kong	HKD 2.34 million	HKD 2.34 million
Bumrungrad Myanmar Co., Ltd.	Myanmar	USD 0.91 million	-

17.5 Guarantees

As at 30 September 2015, there were outstanding bank guarantees of Baht 27.6 million (31 December 2014: Baht 29.1 million) issued by a bank on behalf of the Company. All were required in the normal course of business e.g. payment of utility expenses and space rental.

17.6 Contingent liabilities arising from agreement to acquire investments in subsidiaries

Health Horizons Enterprises Pte. Ltd. ("HHE"), an overseas subsidiary that is 80% owned by the Company, has contingent liabilities under the Share Sales and Purchase Agreement, dated 5 March 2014, whereby it acquired common shares of Bumrungrad Mongolia LLC ("BML") and Seoul Seniors Tower LLC ("SST"). The seller is entitled to receive an additional contingent consideration in the form of earn-out payments, provided certain cumulative net profit targets are achieved through 31 December 2016, at a maximum amount of MNT 10,965.9 million.

The Group has reviewed and reassessed the likelihood that the Group will have to pay this additional amount, taking into consideration the economic situation, operating performance and the forecast operating results of SST for the years 2014 to 2016. As at 30 September 2015 and 31 December 2014, the Group estimated that it has no obligation to pay an additional consideration.

18. Events after the reporting period

On 29 October 2015, the Company's Board of Directors passed a resolution to propose to the convertible bondholders and a meeting of the Company's shareholders for approval, amendments to the terms and conditions governing the rights and obligations of the issuer and the bondholders, which extend the tenor of the BH Convertible Bonds Series#1 and Series#2 that mature on 23 August 2017 for a further 10 years, until 23 August 2027, and to cancel the appointment of a bondholders' representative since the collateral for the convertible bonds has already been released. In addition, it is proposed that the name of the BH Convertible Bonds Series#1 and Series#2 be changed to reflect the new maturity date and the release of the collateral for the bonds.

19. Approval of interim financial statements

These interim financial statements were authorised for issue by the Company's Board of Directors on 29 October 2015.